Melina I Morkin1, Pedram Hamrah2. 1. Cornea Service, New England Eye Center/Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA. 2. Cornea Service, New England Eye Center/Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA; Center for Translational Ocular Immunology, Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA. Electronic address: pedram.hamrah@tufts.edu.
Abstract
PURPOSE: Treatment of neuropathic corneal pain (NCP) remains intricate, and involves a long-term combined multistep approach. The self-retained cryopreserved amniotic membrane (PROKERA®, Bio-Tissue, Miami,FL) has been utilized for multiple ocular surface disorders. We evaluate the efficacy, safety, and tolerability of ProKera® Slim [PKS] and ProKera® Clear [PKC] in the treatment of NCP. METHODS: Retrospective case series of 9 patients who received PKS/PKC for the acute treatment of NCP. Patient demographics, prior therapies, clinical examination, duration of PKS/PKC retention, changes in pain severity, corneal subbasal nerve density and morphology by in vivo confocal microscopy (IVCM; HRT3/RCM, Heidelberg Engineering, Heidelberg, Germany), and adverse events were recorded. RESULTS: PKS/PKC were placed in 10 eyes of 9 patients. Pain severity improved by 72.5 ± 8.4% (from 6.3 ± 0.8 to 1.9 ± 0.6, scale 1-10, p = 0.0003) after retention for 6.4 ± 1.1 days. Despite shorter retention for 4.0 ± 0.7 days in patients with ring dysesthesia (4 eyes) or premature implant disengagement (2 eyes), pain severity still improved by 63.1 ± 12.5% (from 6.8 ± 1.0 to 2.4 ± 0.9, p = 0.009). During a follow-up of 9.3 ± 0.8 months, two patients reported recurrence of pain after 2.3 and 9.6 months respectively, treated effectively with additional PKS/PKC. IVCM showed a 36.6 ± 17.6% increase in total nerve density, from 17,700.9 ± 1315.7 to 21,891.3 ± 2040.5 μm/mm2 (p = 0.047), while the fellow PKS/PKC-untreated eyes did not show a significant interval change. Main nerve trunk and branch nerve densities were not statistically different. Dendritiform cell density decreased from 46.0 ± 8.2 to 32.0 ± 6.0 cells/mm2 (p = 0.01). CONCLUSIONS: PKS/PKC provide a safe and effective treatment approach to achieve sustained pain control in patients with NCP.
PURPOSE: Treatment of neuropathic corneal pain (NCP) remains intricate, and involves a long-term combined multistep approach. The self-retained cryopreserved amniotic membrane (PROKERA®, Bio-Tissue, Miami,FL) has been utilized for multiple ocular surface disorders. We evaluate the efficacy, safety, and tolerability of ProKera® Slim [PKS] and ProKera® Clear [PKC] in the treatment of NCP. METHODS: Retrospective case series of 9 patients who received PKS/PKC for the acute treatment of NCP. Patient demographics, prior therapies, clinical examination, duration of PKS/PKC retention, changes in pain severity, corneal subbasal nerve density and morphology by in vivo confocal microscopy (IVCM; HRT3/RCM, Heidelberg Engineering, Heidelberg, Germany), and adverse events were recorded. RESULTS:PKS/PKC were placed in 10 eyes of 9 patients. Pain severity improved by 72.5 ± 8.4% (from 6.3 ± 0.8 to 1.9 ± 0.6, scale 1-10, p = 0.0003) after retention for 6.4 ± 1.1 days. Despite shorter retention for 4.0 ± 0.7 days in patients with ring dysesthesia (4 eyes) or premature implant disengagement (2 eyes), pain severity still improved by 63.1 ± 12.5% (from 6.8 ± 1.0 to 2.4 ± 0.9, p = 0.009). During a follow-up of 9.3 ± 0.8 months, two patients reported recurrence of pain after 2.3 and 9.6 months respectively, treated effectively with additional PKS/PKC. IVCM showed a 36.6 ± 17.6% increase in total nerve density, from 17,700.9 ± 1315.7 to 21,891.3 ± 2040.5 μm/mm2 (p = 0.047), while the fellow PKS/PKC-untreated eyes did not show a significant interval change. Main nerve trunk and branch nerve densities were not statistically different. Dendritiform cell density decreased from 46.0 ± 8.2 to 32.0 ± 6.0 cells/mm2 (p = 0.01). CONCLUSIONS:PKS/PKC provide a safe and effective treatment approach to achieve sustained pain control in patients with NCP.
Authors: Shruti Aggarwal; Ahmad Kheirkhah; Bernardo M Cavalcanti; Andrea Cruzat; Clara Colon; Emma Brown; David Borsook; Harald Prüss; Pedram Hamrah Journal: Ocul Surf Date: 2015-02-20 Impact factor: 5.033
Authors: Gowri Pachigolla; Pawan Prasher; Mario A Di Pascuale; James P McCulley; John G McHenry; V Vinod Mootha Journal: Eye Contact Lens Date: 2009-07 Impact factor: 2.018
Authors: Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor Journal: Drugs Date: 2020-04 Impact factor: 9.546
Authors: Brian Shafer; Nicole M Fuerst; Mina Massaro-Giordano; Vincent Palladino; Taylor Givnish; Ilaria Macchi; Michael E Sulewski; Stephen E Orlin; Vatinee Y Bunya Journal: Digit J Ophthalmol Date: 2019-06-08
Authors: Holly Rose Chinnery; Rajni Rajan; Haihan Jiao; Mengliang Wu; Alexis Ceecee Zhang; Manikkuwadura Eranda Harshan De Silva; Eve Makrai; Mary Ann Stepp; Nick Di Girolamo; Laura Elizabeth Downie Journal: Br J Ophthalmol Date: 2021-02-10 Impact factor: 5.908
Authors: Marguerite B McDonald; Hosam Sheha; Sean Tighe; Susan B Janik; Frank W Bowden; Amit R Chokshi; Michael A Singer; Seema Nanda; Mujtaba A Qazi; Damon Dierker; Adam T Shupe; Brittany J McMurren Journal: Clin Ophthalmol Date: 2018-04-09